Non-Alcoholic Fatty Liver disease. Fatty (change of) liver, not elsewhere classified Nonalcoholic fatty liver disease [NAFLD]
Conditions
Interventions
Intervention 1: Control group: After referral of the patient from the gastroenterologist, both the control and intervention groups are examined based on criteria for entering the study and are descri
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
19 Years to 60 Years
Inclusion criteria
Inclusion criteria: Diagnosis by specialist physician BMI greater than 25 capability to moderate physical activity Age between 19to 60 years Access to smart phones under the Android capability to work it Informed consent and interest in participating in the study Lack of liver disease such as viral ,autoimmune or medication hepatitis Lack of Wilson, hemochromatosis, hyper or hypothyroidism, diabetes, Addison Lack of gallstone, bile cancer, corticosteroid obesity, Cushing's syndrome Lack of tuberculosis, lipid disorders, alcohol and drug abuse Not using hepatotoxic drugs in the last 6 months, Non-exposure to petrochemicals
Exclusion criteria
Exclusion criteria: Unwillingness to participate in the study Not using self-care app for one month Failure to answer the phone for follow up and no presence in the clinic for two consecutive months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood glucose. Timepoint: Before and 12 weeks after the intervention. Method of measurement: Examination of blood patient in laboratory.;Blood triglyceride. Timepoint: Before and 12 weeks after the intervention. Method of measurement: Examination of blood patient in laboratory.;Lifestyle score is in the Lifestyle ?Questionnaire. Timepoint: Before intervention and one and two and three months after the intervention. Method of measurement: Measurement is done with life style questionnaire which has 32 questions in the Likert spectrum and are scored. always (3), usually (2) or sometimes (1) and never (0) and It has dimensions of physical health and disease prevention, sports and health, weight control and nutrition, psychological health, social health, and the prevention of drugs and drugs.;Blood cholesterol. Timepoint: Before and 12 weeks after the intervention. Method of measurement: Examination of blood patient in laboratory.;Blood Alanin aminotransferase. Timepoint: Before and 12 weeks after the intervention. Method of measurement: Examination of blood patient in laboratory.;Blood Aspartate aminotransferase. Timepoint: Before and 12 weeks after the intervention. Method of measurement: Examination of blood patient in laboratory.;Blood Albumin. Timepoint: Before and 12 weeks after the intervention. Method of measurement: Examination of blood patient in laboratory.;Homeostasis model assessment Insulin resistance). Timepoint: Before and 12 weeks after the intervention. Method of measurement: Measurement of fasting serum insulin in the laboratory and it is calculated as fasting insulin (micronutrile bromolitre), multiplied by fasting blood glucose (mgol / liter) divided by 22.5.;High density lipoprotein. Timepoint: Before and 12 weeks after the intervention. Method of measurement: Examination of blood patient in laboratory.;Low density lipoprotein. Timepoint: Before and 12 weeks after the intervention. Method of measurement: Examination of blood | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRoya Rahmani
Tehran University of Medical Sciences
Outcome results
None listed